TMEM16A Antibody | 5419

TMEM16A Antibody | 5419 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human, Mouse

Homology: N/A

Immunogen: TMEM16A antibody was raised against a 17 amino acid synthetic peptide from near the amino terminus of human TMEM16A.
The immunogen is located within amino acids 70 - 120 of TMEM16A.

Research Area: Signal Transduction

Tested Application: E, WB

Application: TMEM16A antibody can be used for detection of TMEM16A by Western blot at 1 μg/mL.
Antibody validated: Western Blot in human samples. All other applications and species not yet tested.

Specificiy: N/A

Positive Control 1: Cat. No. 1203 - A549 Cell Lysate

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: TMEM16A Antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: TMEM16A Antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: TMEM16A antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: TMEM16A Antibody: DOG1, TAOS2, ORAOV2, TMEM16A, DOG1, Anoctamin-1, Discovered on gastrointestinal stromal tumors protein 1

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: TMEM16A Antibody: Calcium-activated chloride channels (CaCC) are present in many cell types and mediate physiological functions such as epithelial secretion, sensory signal transduction, and smooth muscle contraction. Subunits of these CaCC's include the transmembrane proteins TMEM16A and TMEM16B. TMEM16A is expressed in epithelial cells of the kidney and lung, pancreas, and sensory neurons and its mRNA is seen in foregut, airway epithelia, and tracheal smooth muscle; mice lacking TMEM16A fail to survive past ten days and show aerophagia and little weight gain. TMEM16A is also overexpressed or amplified in multiple cancers associated with poor survival such as oral cancers and gastrointestinal stromal tumors, suggesting the development of CaCC modulators may be a viable therapeutic strategy.